Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $427.96 | 14 | 95.6% |
| Education | $19.62 | 1 | 4.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Relypsa, Inc. | $119.85 | 1 | $0 (2018) |
| AstraZeneca Pharmaceuticals LP | $90.59 | 4 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $69.60 | 3 | $0 (2024) |
| Amgen Inc. | $48.45 | 2 | $0 (2019) |
| Otsuka America Pharmaceutical, Inc. | $45.20 | 2 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $31.15 | 1 | $0 (2023) |
| Mallinckrodt Hospital Products Inc. | $30.46 | 1 | $0 (2024) |
| Noden Pharma USA Inc | $12.28 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $110.89 | 4 | Mallinckrodt Hospital Products Inc. ($30.46) |
| 2023 | $71.80 | 3 | Bayer Healthcare Pharmaceuticals Inc. ($40.65) |
| 2022 | $16.50 | 1 | AstraZeneca Pharmaceuticals LP ($16.50) |
| 2020 | $24.20 | 1 | AstraZeneca Pharmaceuticals LP ($24.20) |
| 2019 | $50.77 | 2 | Amgen Inc. ($29.24) |
| 2018 | $141.93 | 2 | Relypsa, Inc. ($119.85) |
| 2017 | $31.49 | 2 | Amgen Inc. ($19.21) |
All Payment Transactions
15 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/07/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $23.12 | General |
| Category: NEPHROLOGY | ||||||
| 10/30/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $28.95 | General |
| Category: Cardio-renal | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $28.36 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/18/2024 | Mallinckrodt Hospital Products Inc. | TERLIVAZ (Drug) | Food and Beverage | In-kind items and services | $30.46 | General |
| Category: CRITICAL CARE | ||||||
| 12/12/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $31.15 | General |
| Category: DIABETES | ||||||
| 06/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: Cardio-renal | ||||||
| 06/22/2023 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Education | In-kind items and services | $19.62 | General |
| Category: Cardio-renal | ||||||
| 10/26/2022 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $16.50 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 09/16/2020 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $24.20 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/17/2019 | Amgen Inc. | Parsabiv (Biological) | Food and Beverage | In-kind items and services | $29.24 | General |
| Category: Nephrology | ||||||
| 04/11/2019 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $21.53 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 10/08/2018 | Relypsa, Inc. | Veltassa (Drug) | Food and Beverage | In-kind items and services | $119.85 | General |
| Category: Hyperkalemia | ||||||
| 09/26/2018 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $22.08 | General |
| Category: NEPHROLOGY | ||||||
| 10/10/2017 | Noden Pharma USA Inc | Tekturna (Drug) | Food and Beverage | In-kind items and services | $12.28 | General |
| Category: Hypertension | ||||||
| 08/22/2017 | Amgen Inc. | Sensipar (Drug) | Food and Beverage | In-kind items and services | $19.21 | General |
| Category: Nephrology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 8 | 453 | 1,415 | $314,540 | $192,321 |
| 2022 | 10 | 514 | 1,680 | $316,895 | $224,692 |
| 2021 | 8 | 482 | 1,730 | $329,210 | $224,946 |
| 2020 | 9 | 529 | 1,913 | $376,675 | $224,673 |
All Medicare Procedures & Services
35 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 27 | 242 | $99,900 | $69,767 | 69.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 111 | 489 | $53,790 | $43,071 | 80.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 146 | 399 | $71,400 | $41,941 | 58.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 64 | 84 | $17,360 | $12,372 | 71.3% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2023 | 37 | 117 | $38,025 | $10,192 | 26.8% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 22 | 38 | $19,000 | $6,875 | 36.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 32 | 32 | $11,175 | $6,092 | 54.5% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 14 | 14 | $3,890 | $2,011 | 51.7% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 32 | 294 | $102,900 | $82,817 | 80.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 146 | 627 | $68,970 | $55,126 | 79.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 138 | 431 | $61,870 | $43,242 | 69.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 91 | 112 | $23,135 | $18,443 | 79.7% |
| 90937 | Hemodialysis procedure requiring repeated evaluation | Facility | 2022 | 41 | 123 | $39,975 | $11,102 | 27.8% |
| 90961 | Dialysis services, 2-3 physician visits per month (20 years or older) | Office | 2022 | 14 | 24 | $7,200 | $5,804 | 80.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 17 | 17 | $4,905 | $3,120 | 63.6% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 12 | 12 | $2,640 | $1,751 | 66.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 12 | 12 | $3,200 | $1,648 | 51.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 11 | 28 | $2,100 | $1,638 | 78.0% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 31 | 288 | $100,800 | $81,510 | 80.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 127 | 636 | $69,960 | $56,572 | 80.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 142 | 461 | $63,200 | $45,689 | 72.3% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 79 | 100 | $20,300 | $16,415 | 80.9% |
| 90937 | Hemodialysis procedure with repeated evaluations | Facility | 2021 | 49 | 178 | $57,850 | $16,183 | 28.0% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 11 | 17 | $8,500 | $3,211 | 37.8% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 23 | 30 | $4,200 | $2,760 | 65.7% |
About Dr. Syeda Ali, MD
Dr. Syeda Ali, MD is a Nephrology healthcare provider based in Pasadena, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/31/2005. The National Provider Identifier (NPI) number assigned to this provider is 1528051984.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Syeda Ali, MD has received a total of $447.58 in payments from pharmaceutical and medical device companies, with $110.89 received in 2024. These payments were reported across 15 transactions from 8 companies. The most common payment nature is "Food and Beverage" ($427.96).
As a Medicare-enrolled provider, Ali has provided services to 1,978 Medicare beneficiaries, totaling 6,738 services with total Medicare billing of $866,631. Data is available for 4 years (2020–2023), covering 35 distinct procedure/service records.
Practice Information
- Specialty Nephrology
- Location Pasadena, CA
- Active Since 08/31/2005
- Last Updated 07/08/2007
- Taxonomy Code 207RN0300X
- Entity Type Individual
- NPI Number 1528051984
Products in Payments
- Veltassa (Drug) $119.85
- Kerendia (Drug) $69.60
- LOKELMA (Drug) $45.73
- JYNARQUE (Drug) $45.20
- FARXIGA (Drug) $44.86
- JARDIANCE (Drug) $31.15
- TERLIVAZ (Drug) $30.46
- Parsabiv (Biological) $29.24
- Sensipar (Drug) $19.21
- Tekturna (Drug) $12.28
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Nephrology Doctors in Pasadena
Dr. Ka-Lok Tse, M.d, M.D
Nephrology — Payments: $75,671
Vijay Koka, Md, MD
Nephrology — Payments: $4,154
Matthew Kim, Do, DO
Nephrology — Payments: $3,092
Dr. Ann Moore, Md, MD
Nephrology — Payments: $2,783
Dr. Ilian Marquez, M.d, M.D
Nephrology — Payments: $1,539
Sevag Balikian, M.d, M.D
Nephrology — Payments: $1,310